- Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 - - Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib - - Statistically Significant Improvements Observed in NT-proBNP and ECHO Measures of Cardiac Structure and Function - - Consistently Positive Results

- Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - $304 million in cash, cash equivalents & marketable securities, as of September 30, 2022 - SAN DIEGO --(BUSINESS WIRE)--Nov. 3, 2022-- Gossamer Bio, Inc.

- Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - CNS-penetrant GB5121 doses first patient in Phase 1b/2 STAR CNS Study in PCNSL and other rare CNS malignancies - - $342 million in cash, cash equivalents & marketable securities,

SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2022-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced today it has agreed to

SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2022-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of

- Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expected in the fourth quarter of 2022 - - Cash, cash equivalents & marketable securities totaled $272 million as of March 31, 2022 - SAN DIEGO --(BUSINESS WIRE)--May 10,

— Study did not meet primary or secondary endpoints at week 12 — — GB004 Phase 2 SHIFT-UC Study to be terminated for lack of treatment benefit — — Target enrollment reached in Phase 2 TORREY Study of seralutinib in PAH; topline results expected in 4Q22 — — As of March 31, 2022 , Gossamer estimates

- GB004 topline results for the Phase 2 SHIFT-UC study in mild-to-moderate UC expected in the second quarter of 2022 - - Seralutinib (GB002) topline results for the Phase 2 TORREY study in PAH expected in the second half of 2022, subject to developments in the ongoing COVID-19 pandemic - - Cash,

SAN DIEGO --(BUSINESS WIRE)--Feb. 28, 2022-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will